

Author(s): Ranran Kan
Question: Semaglutide compared to control for MASH
Setting:
Bibliography:

Certainty assessment							N ₂ of patients		Effect		Certainty	Importance
N ₂ of studies	Study design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other considerations	semaglutide	control	Relative (95% CI)	Absolute (95% CI)		
MASH resolution (follow-up: range 48 weeks to 72 weeks; assessed with: RR)												
3	randomised trials	not serious	not serious	not serious	not serious	none	487/821 (59.3%)	113/370 (30.5%)	RR 1.98 (1.57 to 2.50)	299 more per 1,000 (from 174 more to 458 more)	⊕⊕⊕⊕ High	CRITICAL
								20.0%		196 more per 1,000 (from 114 more to 300 more)		
Improvement in liver fibrosis (follow-up: range 48 to 72; assessed with: RR)												
3	randomised trials	not serious	serious ^a	not serious	not serious	none	326/821 (39.7%)	100/370 (27.0%)	RR 1.18 (0.74 to 1.88)	49 more per 1,000 (from 70 fewer to 238 more)	⊕⊕⊕⊖ Moderate ^a	CRITICAL
								20.0%		36 more per 1,000 (from 52 fewer to 176 more)		
liver steatosis (follow-up: range 32 weeks to 72 weeks; assessed with: MD)												
4	randomised trials	serious ^b	serious ^a	not serious	not serious	strong association	394	209	-	MD 11.3 lower (18.7 lower to 3.91 lower)	⊕⊕⊕⊖ Moderate ^{a,b}	IMPORTANT
liver stiffness (follow-up: range 35 weeks to 72 weeks; assessed with: MD)												
5	randomised trials	serious ^c	not serious	not serious	not serious	none	876	500	-	MD 0.88 lower (1.91 lower to 0.15 higher)	⊕⊕⊕⊖ Moderate ^c	IMPORTANT
fibrosis test score (follow-up: range 35 weeks to 72 weeks)												
3	randomised trials	serious ^c	serious ^a	not serious	not serious	none	295	200	-	MD 0.26 lower (0.63 lower to 0.11 higher)	⊕⊕⊖⊖ Low ^{a,c}	IMPORTANT
enhanced liver fibrosis (assessed with: MD)												
4	randomised trials	serious ^b	not serious	not serious	not serious	none	868	505	-	MD 0.49 lower (0.29 lower to 0.7 lower)	⊕⊕⊕⊖ Moderate ^b	IMPORTANT
ALT (follow-up: range 12 weeks to 72 weeks; assessed with: MD)												
10	randomised trials	serious ^{b,c}	serious ^a	not serious	not serious	strong association dose response gradient	2513	1494	-	MD 5.55 - lower (9.21 lower to 1.89 lower)	⊕⊕⊕⊕ High ^{a,b,c}	IMPORTANT

CI: confidence interval; MD: mean difference; RR: risk ratio

Explanations

- a. Significant heterogeneity
b. The proportion of the number of people lost to follow-up in the two groups is mildly unbalanced in Romero-Gomez et al.
c. The proportion of people lost to follow-up is mildly unbalanced in Filint et al.